Restructuring Proposal
May 18, 2022
Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces that the enclosed restructuring proposal (the “Restructuring Proposal”) will be submitted to the Danish Maritime and Commercial High Court (the “Court”) and be sent to the Company’s known creditors following the agreement with KemPharm Denmark A/S to sell substantially all of its assets and business activities (the “Assets”), which is conditional upon the approval by the creditors and the affirmation of the Restructuring Proposal by the Court (please see company announcement no. 24/2022).
Restructuring proposal including appendices
Read moreUpdated Financial Calendar for 2022
May 16, 2022
Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces an update to the Company’s financial calendar for the remainder of 2022 following the signing of a binding agreement with KemPharm, Inc. for sale of substantially all of the company’s assets and business activities during the Company’s in-court restructuring proceedings (see company announcement no. 24/2022).
Updated Financial Calendar for 2022
Read moreOrphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.
May 15, 2022
Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC), announces today that it has signed an agreement to sell substantially all of the Company’s assets and business activities to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm Inc. (KMPH: NASDAQ, NY). KemPharm is a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system diseases.
Read moreOrphazyme announces update on in-court restructuring proceedings
Apr 29, 2022
Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces an update to the in-court restructuring proceedings of the Company (please see company announcement no. 10/2022 and 11/2022).
Orphazyme announces update on in court restructuring proceedings
Read moreUpdated Financial Calendar for 2022
Apr 28, 2022
Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces an update to the Company’s Financial Calendar for the remainder of 2022 following the current status of the in-court restructuring proceedings of the Company (please see company announcements no. 10/2022 and 11/2022).
Updated Financial Calendar for 2022
Read moreStatutory restructuring plan adopted by creditors
Apr 7, 2022
Orphazyme A/S in restructuring (ORPHA.CO) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces that today an in-court meeting was held where the statutory restructuring plan as proposed and published by the Company through company announcement no. 15/2022 on March 31, 2022 and company announcement no. 17/2022 on April 4, 2022, was adopted by the Company’s creditors in accordance with section 11 e of the Danish Insolvency Act. No amendments to the restructuring proposal were made at the meeting.
Statutory restructuring plan adopted by creditors
Read moreUpdated Financial Calendar for 2022
Apr 6, 2022
Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces an update to the Company’s Financial Calendar for the remainder of 2022.
Updated Financial Calendar for 2022
Read moreNotice received from the Depositary to holders of ADSs regarding termination of Deposit Agreement
Apr 6, 2022
Orphazyme A/S in restructuring (ORPHA.CO) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, has today received a notice from The Bank of New York Mellon, as depositary (the “Depositary”), that a notification has been sent to holders of American Depositary Shares (“ADSs”) evidenced by American Depositary Receipts (“ADRs”) representing deposited common shares of the Company, regarding termination of the Deposit Agreement dated September 28, 2020 among the Company, the Depositary, and Owners and ADR Holders (the “Deposit Agreement”).
Notice received from the Depositary to holders of ADSs regarding termination of Deposit Agreement
Read moreCorrection: Proposal for a statutory restructuring plan
Apr 4, 2022
Orphazyme A/S in restructuring (ORPHA.CO) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, today announced that, in respect to company announcement no. 15/2022 dated March 31, 2022, the Company has been made aware of a typographical error in the header of the table included in Appendix 1B regarding the interim set-off balance as of March 11, 2022.
Correction Proposal for a statutory restructuring plan
Read moreVoluntary delisting of ADSs has become effective
Mar 31, 2022
Orphazyme A/S in restructuring (ORPHA.CO) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, today announces that following the Company’s voluntary delisting of the Company’s American Depositary Shares (“ADSs”) representing its ordinary shares from Nasdaq Global Select Market (“Nasdaq Global”) (please see company announcement no. 12/2022) has become effective on March 31, 2022.
Voluntary delisting of ADSs has become effective
Read more